Avasimibe

Key Product Details

Product Description

Avasimibe is an ACAT inhibitor (IC₅₀ = 3.3 μM). Inhibits cholesterol esterification and reduces plasma cholesterol levels in rats. Also inhibits tumor growth and prolongs survival time in a melanoma mouse model and reduces tumor growth and metastasis in a pancreatic cancer mouse model.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Product Specifications for Avasimibe

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Avasimibe

The following data is based on the product molecular weight 501.72.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.99 mL	9.97 mL	19.93 mL
5 mM	0.40 mL	1.99 mL	3.99 mL
10 mM	0.20 mL	1.00 mL	1.99 mL
50 mM	0.04 mL	0.20 mL	0.40 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Yang Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 2016 PMID: 26982734
• Li Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene 2016 PMID: 27132508
• Lee Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J.Med.Chem. 1996 PMID: 8978833

Product Documents for Avasimibe